We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biosensor Technology Enables Rapid Detection of Flu Virus

By LabMedica International staff writers
Posted on 12 Jun 2017
A research team has developed a voltage-sensor for early detection of influenza virus A (H1N1) that is almost 100 times more sensitive than conventional tests, and can distinguish between human and avian strains.

Researchers at Tokyo Medical and Dental University (TMDU; Tokyo, Japan) developed the sensor for early detection of even very low virus concentrations. More...
Such early-stage diagnosis is crucial for averting a potential pandemic outbreak, as antiviral medication must be administered in a timely fashion. Conventional tests for detecting the flu virus are often slow and expensive, and can miss early viral infections. In contrast, the new biosensor measures tiny changes in voltage in an electrically conductive polymer to quickly detect virus concentrations almost 100 times smaller than the limit of currently available kits.

Conductive polymers are a class of carbon-based molecules that conduct electricity, but can also be used in biological environments. Biomolecules can be easily attached to the polymers, allowing them to bind with specific targets. In this study, poly(3,4-ethylenedioxythiophene) (PEDOT) was modified with a functional group that binds with the H1N1 human influenza virus, but not avian influenza strains.

“Conducting polymers have several advantages over inorganic counterparts,” explained corresponding author Yuji Miyahara, “These include the ability to conduct both electrical and ionic carriers, mechanical flexibility, low cytotoxicity, low-cost production by casting or printing, and tunable properties via chemical synthesis or doping.”

To construct the biosensor, the polymer film was placed between two electrodes. When a solution containing H1N1, which carries a tiny positive charge on its exterior shell, was added, some of the viruses stuck to the polymer and increased the voltage measured by the electrodes. This electrical method allows the sensor to detect the presence of miniscule amounts of the virus. Viral loads are often measured in hemagglutination units (HAU). The new sensor can detect viral concentrations as small as 0.013 HAU. By comparison, commercially available kits that use immunochromatographic tests only work for concentrations greater than about 1.13 HAU.

“The device is a good candidate for wearable monitoring and point-of-care testing,” added study coauthor Shoji Yamaoka.

The study, by Hai W et al, was published April 5, 2017, in the journal ACS Applied Materials & Interfaces.

Related Links:
Tokyo Medical and Dental University


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.